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Meningococcal disease is an acute, severe bacterial infection 
caused by Neisseria meningitidis. The most common presenta-
tions of invasive meningococcal infection (IMD) are meningitis 
and sepsis, less common pathologic presentations include focal 
infections. IMD can develop from initial symptoms to death within 
24 hours. As many as 20% of survivors have permanent sequelae. 
Infants < 1 year of age have the highest incidence and adoles-
cents the highest carriage prevalence.
In Italy, the incidence of IMD was 0.25 confirmed cases per 
100,000 in 2011, but this may have been considerably underes-
timated due to under-detection and under-reporting. Recently, 
we estimated the impact of the MenC universal vaccination on 
the burden of meningococcal meningitis in Puglia by assessing 
the completeness of three registration sources (notifications, 
hospitalizations, and laboratory surveillance). The sensitiv-
ity of the three systems was 36.7% (95% CI: 17.5%-57.9%) 
and registrations lost nearly 28 cases/year in the period 2001-
2013.
In the National Surveillance of Invasive Bacterial Diseases, 
serogroup B accounted for 64.9% of samples serotyped in 2011. 
Applying this percentage to the total number of hospitalizations 
for IMD registered in the same year (n = 256), we obtained an 
estimated 166 episodes attributable to serogroup B.
Our work highlights the importance of enhancing surveillance for 
meningococcal disease and strengthening vaccinations against 
all preventable serogroups.
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Summary
Brief overview of meningococcal disease
Meningococcal disease is an acute, severe bacterial in-
fection caused by Neisseria meningitidis. The bacteria 
are transmitted by droplet aerosol or secretions from 
the nasopharynx of colonized people (10% to 20% of 
adolescents and adults are asymptomatic transient carri-
ers). Meningitis is the most common presentation of in-
vasive meningococcal infection (IMD) and results from 
the spread of the bacteria through the bloodstream to the 
brain. Meningococcal sepsis (bloodstream infection or 
meningococcemia) may occur with or without menin-
gitis (5% to 20% of IMDs). Less common pathologic 
presentations include pneumonia (5% to 15% of cases), 
arthritis (2%), otitis media (1%), and epiglottitis (less 
than 1%) [1, 2]. 
IMD is a feared, rapidly progressive childhood infection 
that can develop from initial symptoms (easily misdi-
agnosed) to death within 24 hours [1, 3]. In the first 8 
hours, most children have only non-specific symptoms 
(irritability, loss of appetite, fever, nausea/vomiting, 
sore throat, coryza, general aches, leg pain, drowsiness, 
floppy muscle tone in infants < 1 year of age) that can 
often resemble those of common viral illnesses. Only 
about half these children are sent to hospital after the 
first consultation. Specific meningitis symptoms and 
signs of sepsis and shock (cold hands/feet, petechiae, 
purpuric rash, meningism, neck stiffness, photophobia, 
bulging fontanelle in infants < 1 year of age) are seen 
later, around 12-15 hours from the onset of the illness, 
due to the rapid replication of Neisseria meningitidis in 
the body. The last signs (such as confusion/delirium, un-
consciousness, seizure, septic shock, multisystem fail-
ure, death) develop late, with a median onset of 15-24 
hours. Intervention often does not occur until specific 
late-stage symptoms have already appeared (median 
time from onset to hospital admission = 19 hours) [3, 4].
Even when the disease is diagnosed early and adequate 
treatment is started, 5% to 10% of patients die, typically 
within 24 to 48 hours after the onset of symptoms [2]. 
Potentially lethal complications of fulminant meningo-
coccal disease include increased intracranial pressure, 
uncal herniation (included during lumbar puncture), cer-
ebral infarction, status epilepticus, cardiac arrest, meta-
bolic acidosis, primary respiratory failure, multi-system 
failure, intractable shock, circulatory collapse, dissemi-
nated intravascular coagulation [4-6].
As many as 20% of survivors of IMD (all serogroups) 
have permanent sequelae, such as hearing loss, neuro-
logic damage, or loss of a limb [1]. Most children sur-
vive serogroup B meningococcal disease without major 
sequelae. However, nearly one in ten experience major 
disabling deficits, including limb amputations, seizures 
and hearing loss, and more than a third have one or more 
deficits such as psychological disorders, digit amputa-
tions and unilateral hearing loss [7].
Infants younger than one year of age have the highest in-
cidence (17.3-fold increase over average in Europe) [8] 
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due to a naive/immature immune system, waning of pro-
tective maternal antibody levels and exposure to young 
adult carriers in the household [9, 10]. Adolescents are 
the population with the highest carriage prevalence 
(1.8-5.3-fold increase over other age groups) [11]. Close 
and prolonged contact with a carrier, such as kissing, 
sneezing or coughing on someone, household crowding, 
or living in dormitories, sharing of drinks, cigarettes, 
and utensils, respiratory tract infection, both active and 
passive smoking, travelling to countries with epidemic 
or hyperendemic meningococcal infection are associ-
ated with an increased risk for the disease [12-14]. Most 
cases of meningococcal disease occur in previously 
healthy people without any warning [15].
Under-reporting of meningococcal 
disease incidence in Italy
IMD is rare in Italy where 0.25 confirmed cases per 
100,000 population were observed in 2011, based on 
surveillance data submitted to The European Surveil-
lance System  [16]. Reported incidence, however, may 
be considerably underestimated due to underdiagnosis 
(under-ascertainment) and under-reporting affecting 
IMD surveillance, particularly in some regions [17]. 
Monitoring the incidence of meningococcal disease is 
essential to evaluate the impact of the implemented vac-
cination strategies with the meningococcal serogroup C 
conjugate vaccine (MenC) or the quadrivalent menin-
gococcal conjugate vaccine (MenACWY), and to ad-
vise on the use of the new multicomponent serogroup 
B meningococcal (4CMenB) vaccine, recently intro-
duced in some Italian regions and under discussion for 
introduction on a national scale. In a recent study, we 
estimated the impact of the MenC universal vaccina-
tion on the burden of meningococcal meningitis in Pug-
lia by assessing the completeness (sensitivity) of three 
registration sources (notifications, hospitalizations, and 
laboratory surveillance) in the period 2001-2013. We 
found that only 213 cases of meningococcal meningitis 
out of an estimated 580 (95% CI: 368-1,216) total cases 
were recorded in at least one of the three sources, with 
an overall sensitivity of 36.7% (95% CI: 17.5%-57.9%). 
This means that the routine surveillance systems lost 
nearly 28 cases/year in the study period [18].
Incidence of meningococcal B disease  
in Italy
In order to estimate the potential impact of the new 
4CMenB vaccine, the distribution of N. meningitidis 
serogroups detected by the National Surveillance of 
Invasive Bacterial Diseases (referred to as MIB, 2011 
and 2013 data) was applied to the total number of both 
reported and hospitalized cases in each of the 21 Ital-
ian regions. Hospitalizations were extracted from the 
National Hospital Discharge Registry (HDR, 2011 da-
ta) [19], where IMD is identified by the ICD9-CM codes 
Fig. 1. Number of invasive meningococcal disease cases and estimated distribution of cases attributable to serogroup B, by Italian region, 
2013.
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036.x - Meningococcal infection as main or secondary 
diagnosis. 
In 2013, a total of 172 cases were notified to the MIB 
surveillance (incidence rate of 0.29 per 100,000). 
Among the 116 (67.4%) strains typed, serogroup B ac-
counted for 48.3% of isolates (56 cases, incidence rate 
of 0.09 per 100.000) [20]. Lombardia reported the high-
est notification rate (42 cases, incidence rate of 0.43 
per 100,000)  [20], thus the estimated number of cases 
that could be attributable to serogroup B was 20. Four 
regions (Abruzzo, Liguria, Molise, and Valle d’Aosta) 
reported zero cases (Fig. 1) [20]. 
A total of 256 hospitalizations for IMD were recorded 
in the HDR (hospitalization rate of 0.42 per 100,000) in 
2011. Out of 22 day-hospitals, 13 reported main diagno-
sis coded as meningitis and six were coded as sequelae 
(i.e.: paralytic syndromes, late effects of cerebrovascu-
lar disease, disarticulation of elbow, etc). Applying the 
percentage of the typed B strains in 2011 retrieved from 
the MIB surveillance (76 cases, 64.9% of samples se-
rotyped [20]) to the total number of hospitalizations for 
IMD, we obtained an estimated 166 episodes that could 
be attributable to serogroup B (hospitalization rate of 
0.27 per 100,000). Lombardia confirmed the highest 
rate (45 discharges for IMD; 0.46 per 100,000), with an 
estimated number of 29 cases that could be attributable 
to serogroup B. Molise reported zero hospitalizations for 
IMD (Fig. 2). 
Closing remarks
The incidence of invasive meningococcal disease is rela-
tively low in Italy; however, it is a disease with a high 
fatality rate and high risk of complications [1, 2, 16, 20].
The assessment of the sensitivity of data sources avail-
able for monitoring the incidence of meningococcal 
meningitis showed that they are not sufficiently com-
prehensive in terms of the cases they contain [18]. Both 
under-reporting and under-ascertainment affect the In-
vasive Bacterial Diseases surveillance in some Italian 
regions  [17], complicating efforts to understand their 
occurrence and burden, particularly when the planning 
and evaluation of vaccination programmes need timely, 
reliable incidence data. 
Despite significant differences in reporting practices be-
tween regions, cases from serogroup B remain dominant in 
Italy, as the estimated number of discharge records for IMD 
that could be attributable to group B in our analysis shows. 
Our work highlights the importance of enhancing sur-
veillance for meningococcal disease and strengthening 
vaccination programmes against all preventable menin-
gococcal serogroups.
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